EGFR and neoplasm: Success in reduction of tumor burden and infrequency in cancer recurrence in this trial sparked more clinical trials to be approved and progress forward, which are still ongoing.41 One ongoing Phase 3 clinical trial, which began in 2019, employs the antibody–dye conjugate of cetuximab and IR700 targeting EGFR, ASP-1929, in patients with recurrent head and neck cancer who have failed attempted conventional cancer treatment more than two times previously in three countries in Asia, the US/Canada, and four countries in the EU (NCT03769506).88 This trial will record OS and PFS in patients.